Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain (Ci-FCP)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Status and phase

Terminated

Phase 4

Conditions

Functional Chest Pain

Treatments

Drug: Placebo

Drug: Citalopram 20mg

Study type

Interventional

Funder types

Other

Identifiers

NCT05735756

NL77673.018.21

Details and patient eligibility

About

Non-cardiac chest pain (NCCP) in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called functional chest pain (FCP). Most likely multiple factors play a role, such as esophageal hypersensitivity and enhanced perception. Citalopram and other antidepressants are proven to be effective in the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. With this trial the investigators want to assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.

Full description

Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain (FCP). NCCP in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called FCP. The pathophysiology is not fully understood. Most likely multiple factors play a role, such as esophageal hypersensitivity and enhanced perception. Citalopram and other antidepressants are proven to be effective in the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. However, available data regarding low dose antidepressants in functional chest pain is inconclusive. Moreover, all current evidence concerning the effect of low dose antidepressants in patients with functional chest pain is extracted from trials that pooled patients with different functional esophageal disorders. With this trial the investigators want to assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent
Minimum age: 18 years
Functional chest pain according to Rome IV criteria
Ruled out cardiac origin of chest pain
ECG with corrected QT interval (QTc) within the normal range (<450ms male, <460ms female)
Symptoms of chest pain for at least 6 months
Frequency of symptoms at least once a week
Gastroduodenoscopy, high-resolution manometry and 24-hour pH-impedance monitoring need to have been performed recently.

Exclusion criteria